rs727503207
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM1PM2PP3_Moderate
The NM_000256.3(MYBPC3):c.1213A>G(p.Met405Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000256.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.1213A>G | p.Met405Val | missense_variant | Exon 13 of 35 | 5 | NM_000256.3 | ENSP00000442795.1 | ||
MYBPC3 | ENST00000399249.6 | c.1213A>G | p.Met405Val | missense_variant | Exon 12 of 34 | 5 | ENSP00000382193.2 | |||
MYBPC3 | ENST00000544791.1 | n.1213A>G | non_coding_transcript_exon_variant | Exon 13 of 27 | 5 | ENSP00000444259.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1245704Hom.: 0 Cov.: 49 AF XY: 0.00 AC XY: 0AN XY: 618054
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Cardiomyopathy Pathogenic:1
- -
not specified Uncertain:1
Variant classified as Uncertain Significance - Favor Pathogenic. The Met405Val v ariant in MYBPC3 has been previously reported in 1 adult with HCM (Crehalet 2012 ) and was identified by our laboratory in 2 individuals with HCM (LMM unpublishe d data). This variant was absent from large population studies. Methionine (Met) at position 405 is not conserved in evolutionarily distant species and the chan ge to valine (Val) is present in several birds and reptiles. However, computatio nal prediction tools and in vitro studies (Crehalet 2012) suggest this variant m ay lead to the creation of a novel splice site, which could result in a truncate d or absent protein. In summary, while there is some suspicion for a pathogenic role, the clinical significance of the Met405Val variant is uncertain. -
not provided Uncertain:1
PP3, PM2_supporting, PS3_moderate, PS4_supporting -
Hypertrophic cardiomyopathy Uncertain:1
This sequence change replaces methionine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 405 of the MYBPC3 protein (p.Met405Val). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 25611685, 27532257, 37652022). ClinVar contains an entry for this variant (Variation ID: 164126). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Cardiovascular phenotype Uncertain:1
The c.1213A>G variant (also known as p.M405V), located in coding exon 13 of the MYBPC3 gene, results from an A to G substitution at nucleotide position 1213. The methionine at codon 405 is replaced by valine, an amino acid with highly similar properties. This variant has been reported in hypertrophic cardiomyopathy (HCM) genetic testing cohorts and individuals reported to have HCM; however, clinical details were limited (Crehalet et al. Cardiogen., 2012; 2:e6; Alfares AA et al. Genet. Med., 2015 Nov;17:880-8; Walsh R et al. Genet. Med., 2017 02;19:192-203). This nucleotide position is not well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and will result in the creation or strengthening of a novel splice donor site. Limited studies suggest that this variant may have some impact on splicing (Crehalet et al. Cardiogen., 2012; 2:e6; Ito K et al. Proc. Natl. Acad. Sci. U.S.A., 2017 07;114:7689-7694). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at